Glycopyrronium Bromide Accord Healthcare

Glycopyrronium Bromide Accord Healthcare is a prescription medication that contains the active ingredient glycopyrronium bromide. It is supplied in an injectable form for intramuscular or intravenous administration, with the specific strength provided by Accord Healthcare for use in the European market. The product belongs to the anticholinergic (muscarinic antagonist) class and is used as a bronchodilator in respiratory therapy.

Glycopyrronium Bromide is indicated for the management of chronic obstructive pulmonary disease (COPD) and related airway obstruction. It is employed as a maintenance therapy to improve breathing and reduce symptoms.

- Long‑term treatment of COPD to decrease bronchospasm - Adjunct therapy for patients with persistent airflow limitation - Helps improve lung function and exercise tolerance - May be used when other bronchodilators are insufficient - Supports reduction of mucus secretion in the airways

Side effects of glycopyrronium bromide vary in frequency and severity. Common reactions are usually mild, while serious events are less frequent but require medical attention.

Common: - Dry mouth - Constipation - Urinary retention - Blurred vision - Tachycardia - Headache

Serious: - Severe allergic reaction (rash, swelling, difficulty breathing) - Acute angle‑closure glaucoma - Cardiac arrhythmias - Paradoxical bronchospasm - Persistent urinary retention requiring intervention

Before using glycopyrronium bromide, certain health considerations should be reviewed to ensure safe use.

- Assess for a history of urinary retention, prostate enlargement, or bladder outlet obstruction - Use cautiously in patients with narrow‑angle glaucoma or other ocular disorders - Monitor cardiovascular status in individuals with arrhythmias or heart disease - Consider dose adjustment in hepatic impairment - Evaluate risks versus benefits in elderly patients - Pregnancy and lactation safety data are limited; discuss with a healthcare professional

Glycopyrronium bromide may interact with other medicines, affecting its efficacy or safety profile.

Avoid: - Concurrent use of other anticholinergic agents that may increase anticholinergic burden - Drugs known to prolong the QT interval when combined with glycopyrronium bromide

Use with caution: - Beta‑agonists or other bronchodilators, as additive bronchodilation may occur - Cholinesterase inhibitors used for myasthenia gravis or Alzheimer’s disease - Medications that affect urinary retention, such as antihistamines or tricyclic antidepressants - Cardiovascular drugs that influence heart rate or rhythm